Infection by gram-negative organisms via the biliary route results in greater mortality than portal venous infection.
Cholangitis requires bile duct obstruction and infection. Patients with cholangitis are often more affected than those with infections that reach the liver through the portal vein. We will attempt to study the influences of (i) route of entry and (ii) presence of bile duct obstruction on hepatic infection. C57BL/6 mice received injections of Escherichia coli or lipopolysaccharide into the obstructed bile duct or portal vein and were monitored for survival. Livers were assayed for bacteria, and cytokine mRNA was measured. In order to examine the effect of biliary obstruction on hepatic infection, animals were subjected to bile duct ligation 1 day prior to portal vein injection and were monitored for survival. The 50% lethal dose (LD(50)) for E. coli injected into the bile duct was 50 CFU/animal; the LD(50) for E. coli injected into the portal vein was 5 x 10(7) CFU/animal. Initial hepatic delivery of bacteria was equivalent 1 h after injection into the bile duct or portal vein. However, by 24 h, a significantly greater amount of bacteria was recovered from the livers of the bile duct-injected group. Interleukin 10 (IL-10) and IL-1RA mRNA was expressed at greater levels in the bile duct-injected group. Prior bile duct ligation followed by portal vein injection resulted in a higher incidence of death than when sham operation was performed prior to portal vein injection. Our data suggest that the increased mortality from cholangitis, compared with that from other hepatic infections, is related to the different route of delivery of pathogen and the maladaptive response (possibly involving IL-10 and IL-1RA) to biliary obstruction itself.
Jeyarajah
D Rohan
DR
Department of Surgery, University of Texas Southwestern Medical School, Dallas, Texas 75390-9156, USA. rohan.jeyarajah@utsouthwestern.edu
Kielar
Mariusz L
ML
Frantz
Nicole
N
Lindberg
Guy
G
Lu
Christopher Y
CY
D000818:Animals; D002761:Cholangitis / Q000209:etiology* / Q000382:microbiology; D002779:Cholestasis / Q000150:complications*; D004926:Escherichia coli / Q000502:physiology*; D004927:Escherichia coli Infections / Q000209:etiology*; D006505:Hepatitis / Q000209:etiology* / Q000382:microbiology; D007275:Injections, Intravenous; D007378:Interleukins / Q000096:biosynthesis / Q000235:genetics; D008026:Ligation; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000633:toxicity; D008099:Liver / Q000382:microbiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D011169:Portal Vein; D012333:RNA, Messenger / Q000032:analysis
D007378:Interleukins; D008070:Lipopolysaccharides; D012333:RNA, Messenger